Study to Assess the Efficacy of Brachytherapy With or Without Hormone Therapy, Using Triptorelin 22.5mg in Patients With Recurrence of Prostate Cancer

NCT01374087 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

32

Enrollment

INDUSTRY

Sponsor class

Stopped Slow enrollment of patients.

Conditions

Prostate Cancer

Interventions

DRUG: Triptorelin 22.5 mg
RADIATION: Brachytherapy

Sponsor

Ipsen